Table.
Available vaccines and priority groups in various countries as of March 1, 2021
| Available vaccines | Date of first dose | Priority groups* | Inclusion of patients with cancer? | |
|---|---|---|---|---|
| USA | Pfizer/BioNTech, Moderna, Johnson & Johnson | December, 2020 | Health-care workers; residents of long-term care facilities; people aged >75 years followed by those aged 70–79 years; non-health care frontline essential workers; people aged 65–74 years; people aged 16–64 years with high-risk medical conditions (including cancer) | Prioritised among people aged 16–64 years |
| UK | Pfizer/BioNTech, AstraZeneca, Moderna | December, 2020 | Residents in a care home for older adults and staff working in care homes for older adults; people aged ≥80 years and frontline health and social care workers; people aged ≥75 years; people aged ≥70 years and clinically extremely vulnerable individuals; people aged ≥65 years; people aged 16–65 years in an at-risk group (including cancer) | Prioritised among people aged 16–65 years; people with haematological malignancies; patients receiving chemotherapy or targeted anticancer treatments; patients receiving radiation for lung cancer |
| Australia | Pfizer/BioNTech, AstraZeneca | February, 2021 | Frontline health-care worker subgroups at high risk; nursing home care staff and disability care staff; nursing home care residents and disability care residents; people aged >80 years followed by younger adults; younger adults with underlying medical condition (including cancer and those with disabilities) | Prioritised among younger adults; patients receiving chemotherapy or radiotherapy; patients with haematological cancers diagnosed within the past 5 years; patients with non-haematological cancers diagnosed in the past 12 months; patients who have had a bone marrow transplant in the past 24 months |
| New Zealand | Pfizer/BioNTech | February, 2021 | People older than 65 years and those younger than 65 years with underlying conditions and disabilities† | Not specified |
| Brazil | Instituto Butantan, AstraZeneca | January, 2021 | People aged 60 years and older living in long-term care facilities; indigenous populations; health-care workers; people aged ≥60 years living in the community; younger adults with comorbidities | Patients aged <60 years who received chemotherapy or radiotherapy in previous 6 months |
| Mexico | AstraZeneca, Pfizer/BioNTech, Sputnik V, Sinovac | December, 2020 | Frontline health-care workers; people aged ≥60 years regardless of comorbidities; people aged <60 years with comorbidities (including cancer) | Prioritised among people aged <60 years |
| India | Covaxin, Covishield (AstraZeneca/Serum Institute of India) | January, 2021 | Health-care workers; frontline workers (police, prison staff, municipal workers); people aged ≥50 years and people aged <50 years with comorbidities (including cancer) | Prioritised only among people aged <50 years |
| Russia | Sputnik V, EpiVacCorona, CoviVac | December, 2020 | Social and health-care workers; people aged ≥60 years; people aged <60 years with comorbidities (including cancer) | Prioritised only among people aged <60 years |
| China | Sinovac, Sinopharm | December, 2020 | No prioritisation for older adults (it is recommended that vaccination is postponed for people aged >59 years, those with cancer, and those who are on immunomodulators such as anticancer drugs) | Excluded |
| Hong Kong | Sinovac, Pfizer/BioNTech | February, 2021 | Residents and staff of residential care homes for older people and people with disabilities and other institutional facilities; workers in health-care settings, workers in other essential services who are at increased risk of exposure to COVID-19, and people aged ≥60 years; people aged 16–59 years with chronic medical conditions | Not specified (potentially prioritised among people aged 16–59 years) |
Data sources are provided in the appendix.
*
Listed in order of prioritisation.
†
In the context of widespread community transmission but not in the context of low or no community transmission or clusters and controlled outbreaks (as of March 2, 2021, prioritisation is based on low or no community transmission).